READ OUR 2025 REPORT TO READERS

Recent Quotes
My Watchlist
Indicators
New Hampshire Stocks
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Moderna, Inc. - Common Stock (NQ:MRNA)

49.81 +6.81 (+15.84%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 21, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Moderna, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Discover which S&P500 stocks are making waves on Wednesday. ↗
Via Chartmill
News headline image
Moderna Stock Skyrockets To 52-Week High: What&#39;s Behind The Surge? ↗
Moderna Inc (NASDAQ:MRNA) shares are trading higher on Wednesday on continued momentum after the company's Tuesday update revealing the long‑term results from a cancer therapy study. 
Via Benzinga
What's going on in today's session: S&P500 movers ↗
Via Chartmill
News headline image
Moderna (MRNA) Shares Skyrocket, What You Need To Know
Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 8.8% in the afternoon session after the company, in partnership with Merck, announced positive results from a five-year follow-up study of... 
Via StockStory
Topics Artificial Intelligence Government
ABUS Stock On Track For Biggest Intraday Drop In Over 5 Years – What’s The Issue Around Its Patent In Europe? ↗
Via Stocktwits
Topics Intellectual Property
Gapping S&P500 stocks in Monday's session ↗
Via Chartmill
News headline image
Moderna Stock Still Worth 37% Less After Cancer Vaccine Data? BofA’s New Price Target Keeps Retail Traders Cautious ↗
BofA Securities said the target hike reflects higher sales expectations, despite logistics challenges. 
Via Stocktwits
News headline image
Moderna Pops 17%—Is There Life in MRNA, Down 90% from COVID High? ↗
Via MarketBeat
News headline image
Moderna Shares Rise On Five-Year Follow-Up Takeaways For Skin Cancer Vaccine: Retail Applauds ‘Solid’ Update ↗
Intismeran autogene vaccine, in combination with cancer drug Keytruda, reduced the risk of recurrence or death at five years of follow-up, the company said. 
Via Stocktwits
News headline image
Moderna & Merck Announce 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA(R) (pembrolizumab) Demonstrated Sustained Improvement in the Primary Endpoint of Recurrence-Free Survival in Patients With High-Risk Stage III/IV Melanoma Following
Via ACCESS Newswire
News headline image
3 Healthcare Stocks Walking a Fine Line
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Players catalyzing medical advancements have benefited from elevated demand, and... 
Via StockStory
Topics Stocks
Exploring the top movers within the S&P500 index during today's session. ↗
Via Chartmill
These S&P500 stocks are moving in today's session ↗
Via Chartmill
News headline image
The mRNA 2.0 Inflection: A Deep Dive into Moderna (MRNA) as it Faces a Critical 2026
As of January 16, 2026, Moderna, Inc. (NASDAQ: MRNA) stands at a critical crossroads. Once the poster child for the biotechnology industry’s rapid response to a global pandemic, the Cambridge-based... 
Via Finterra
Topics Initial Public Offering Intellectual Property Lawsuit
Top S&P500 movers in Friday's pre-market session ↗
Via Chartmill
Chips and Checks: AI and Banks Lead Wall Street's Charge ↗
Via Chartmill
Topics Artificial Intelligence
News headline image
The Execution Engine: How Merck is Dominating the 2026 Pharma Landscape
As of January 15, 2026, Merck & Co. (NYSE: MRK) has emerged as the standout performer in the pharmaceutical sector, defying the gravity of looming patent expirations with a series of strategic... 
Via MarketMinute
Topics Economy Intellectual Property
News headline image
Moderna’s High-Stakes Transformation: Navigating the Post-Pandemic Pivot
Once the poster child for the biotechnology sector’s rapid response to the global pandemic, Moderna, Inc. (Nasdaq: MRNA) finds itself at a critical crossroads in early 2026. After a tumultuous period... 
Via Finterra
Topics Initial Public Offering Intellectual Property
Trump’s Iran Tariff Threat Lit a Fuse Under Oil — and Wall Street Still Sold It ↗
Via Chartmill
Topics Government
These S&P500 stocks are moving in today's session ↗
Via Chartmill
Stay informed with the top movers within the S&P500 index on Tuesday. ↗
Via Chartmill
News headline image
The mRNA Pivot: Moderna Navigates Regulatory Headwinds and Tariff Turmoil in a Volatile 2026 Biotech Landscape
As the 44th Annual J.P. Morgan Healthcare Conference concludes in early January 2026, Moderna, Inc. (NASDAQ: MRNA) finds itself at a critical crossroads. Once the darling of the pandemic era, the... 
Via MarketMinute
Topics Economy Intellectual Property World Trade
Top S&P500 movers in Monday's session ↗
Via Chartmill
What's going on in today's session: S&P500 movers ↗
Via Chartmill
These S&P500 stocks are moving in today's pre-market session ↗
Via Chartmill
News headline image
Moderna Provides Business and Pipeline Updates at 44th Annual J.P. Morgan Healthcare Conference
Via ACCESS Newswire
News headline image
BioNTech Finalizes CureVac Acquisition: A Strategic Consolidation Met with Market Skepticism
In a move that signals the end of an era for independent mRNA pioneers, BioNTech SE (Nasdaq: BNTX) has officially completed its acquisition of longtime rival CureVac N.V. (Nasdaq: CVAC). The... 
Via MarketMinute
Topics Intellectual Property
News headline image
Moderna’s Second Act: A 2026 Deep Dive into the Future of mRNA Therapeutics
Today’s Date: January 9, 2026 Introduction As we enter the first weeks of 2026, Moderna, Inc. (NASDAQ: MRNA) finds itself at a defining crossroads. Once the poster child for the biotech boom of the... 
Via PredictStreet
Topics Initial Public Offering Intellectual Property
News headline image
3 Unprofitable Stocks We Keep Off Our Radar
Unprofitable companies face headwinds as they struggle to keep operating expenses under control. Some may be investing heavily, but the majority fail to convert spending into sustainable growth. 
Via StockStory
News headline image
Dow Jones Erases Record Highs in 200-Point Reversal as Economic Data Shifts
The Dow Jones Industrial Average (DJIA) experienced a jarring reversal on Wednesday, January 7, 2026, tumbling more than 200 points after hitting a fresh all-time high earlier in the session. The... 
Via MarketMinute
Topics Artificial Intelligence Economy Stocks
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Gift this article